Literature DB >> 16297638

Expression, purification, and characterization of Clostridium botulinum type B light chain.

Janice Gilsdorf1, Nizamettin Gul, Leonard A Smith.   

Abstract

A full-length synthetic gene encoding the light chain of botulinum neurotoxin serotype B, approximately 50 kDa (BoNT/B LC), has been cloned into a bacterial expression vector pET24a+. BoNT/B LC was expressed in Escherichia coli BL21.DE3.pLysS and isolated from the soluble fraction. The resultant protein was purified to homogeneity by cation chromatography and was determined to be >98% pure as assessed by SDS-polyacrylamide gel stained with SilverXpress and analyzed by densitometry. Mass spectroscopic analysis indicated the protein to be 50.8 kDa, which equaled the theoretically expected mass. N-terminal sequencing of the purified protein showed the sequence corresponded to the known reported sequence. The recombinant BoNT/B light chain was found to be highly stable, catalytically active, and has been used to prepare antisera that neutralizes against BoNT/B challenge. Characterization of the protein including pH, temperature, and the stability of the protein in the presence or absence of zinc is described within. The influence of pH differences, buffer, and added zinc on secondary and tertiary structure of BoNT/B light chain was analyzed by circular dichroism and tryptophan fluorescence measurements. Optimal conditions for obtaining maximum metalloprotease activity and stabilizing the protein for long term storage were determined. We further analyzed the thermal denaturation of BoNT/B LC as a function of temperature to probe the pH and added zinc effects on light chain stability. The synthetic BoNT/B LC has been found to be highly active on its substrate (vesicle associated membrane protein-2) and, therefore, can serve as a useful reagent for BoNT/B research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297638     DOI: 10.1016/j.pep.2005.09.024

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  13 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

2.  Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium.

Authors:  Rahman M Mizanur; John Gorbet; S Swaminathan; S Ashraf Ahmed
Journal:  Int J Biochem Mol Biol       Date:  2012-09-25

3.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

4.  Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.

Authors:  Hai-Hong Wang; Stephen Riding; Paul Lindo; Bal Ram Singh
Journal:  Appl Environ Microbiol       Date:  2010-08-06       Impact factor: 4.792

5.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

6.  Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.

Authors:  Q Meng; C Garcia-Rodriguez; G Manzanarez; M A Silberg; F Conrad; J Bettencourt; X Pan; T Breece; R To; M Li; D Lee; L Thorner; M T Tomic; J D Marks
Journal:  Anal Biochem       Date:  2012-08-21       Impact factor: 3.365

7.  Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.

Authors:  Harry B Hines; Alexander D Kim; Robert G Stafford; Shirin S Badie; Ernst E Brueggeman; David J Newman; James J Schmidt
Journal:  Appl Environ Microbiol       Date:  2007-12-14       Impact factor: 4.792

8.  Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.

Authors:  Virginia Roxas-Duncan; Istvan Enyedy; Vicki A Montgomery; Vanessa S Eccard; Marco A Carrington; Huiguo Lai; Nizamettin Gul; David C H Yang; Leonard A Smith
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

9.  Development of immunodetection system for botulinum neurotoxin type B using synthetic gene based recombinant protein.

Authors:  Swati Jain; S Ponmariappan; Om Kumar
Journal:  Indian J Med Res       Date:  2011-07       Impact factor: 2.375

10.  Tyrosine phosphorylation of botulinum neurotoxin protease domains.

Authors:  Stephen Toth; Ernst E Brueggmann; George A Oyler; Leonard A Smith; Harry B Hines; S Ashraf Ahmed
Journal:  Front Pharmacol       Date:  2012-06-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.